English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

With full interest, we read the article “Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?” by Ruiz-Nodar et al.1 In fact, I commend the authors for conducting this highly interesting piece of research using the newly pioneered HAS-BLED risk score for estimation of bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention. Evidently, the late-breaking innovation of the HAS-BLED bleeding risk score has paved the way for a long-awaited new insight to patients who need long-term oral anticoagulation (OAC) therapy.2 No wonder then that, very shortly …

circulation. cardiovascular interventions

Letter by Nammas Regarding Article, “Should We Recommend Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score?”